Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1903234 | 0.67 | TP53 (0.34) | MEN1ALDH1A1KMT2A | |
| SCHEMBL20185030 | 0.67 | — | — | |
| SCHEMBL7093049 | 0.64 | ADORA2A (0.45) | MEN1ALDH1A1KMT2AMAPK1 | |
| SCHEMBL27301980 | 0.63 | ALDH1A1 (0.38) | MEN1ALDH1A1KMT2AMAPK1 | |
| SCHEMBL1802262 | 0.63 | MAPK1 (0.40) | MEN1ALDH1A1KMT2AMAPK1 | |
| SCHEMBL5674957 | 0.63 | CYP3A4 (0.48) | MEN1ALDH1A1KMT2AMAPK1 | |
| SCHEMBL5757031 | 0.62 | ALDH1A1 (0.38) | ALDH1A1MAPK1 | |
| SCHEMBL978863 | 0.61 | — | — | |
| SCHEMBL6512058 | 0.61 | POLB (0.31) | — | |
| SCHEMBL9515906 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10676468-B2 | N-(3-heteroarylaryl)-4-arylarylcarboxamides and analogs as hedgehog pathway inhibitors and use thereof | IMPACT THERAPEUTICS, INC. (CN) | 2020-06-09 | — | — | US | disclosed |
| EP-3536320-A1 | APPLICATION OF HEDGEHOG PATHWAY INHIBITOR FOR TREATMENT OF FIBROTIC DISEASES | Impact Therapeutics, Inc (CN) | 2019-09-11 | — | — | EP | disclosed |
| US-20190255042-A1 | APPLICATION OF HEDGEHOG PATHWAY INHIBITOR IN TREATING FIBROSIS DISEASES | Impact Therapeutics (Shanghai), Inc (CN) | 2019-08-22 | — | — | US | disclosed |
| US-20150191460-A1 | N-(3-heteroarylaryl)-4-arylarylcarboxamides and Analogs as Hedgehog Pathway Inhibitors and Use Thereof | IMPACT THERAPEUTICS, INC. (CN) | 2015-07-09 | — | — | US | disclosed |
| EP-2875005-A1 | N-(3-HETEROARYLARYL)-4-ARYLARYLCARBOXAMTDES AND ANALOGS AS HEDGEHOG PATHWAY INHIBITORS AND USE THEREOF | Impact Therapeutics, Inc. (CN) | 2015-05-27 | — | — | EP | disclosed |
| WO-2014012511-A1 | N-(3-HETEROARYLARYL)-4-ARYLARYLCARBOXAMTDES AND ANALOGS AS HEDGEHOG PATHWAY INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS, INC. (CN) | 2014-01-23 | — | — | WO | disclosed |
| US-7037916-B2 | Pyrimidine derivatives as IL-8 receptor antagonists | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2006-05-02 | — | — | US | disclosed |
| WO-2004069829-A1 | (2S)-2-((PYRIMIDIN-4-YL)AMINO)-4-METHYLPENTANOIC ACID AMINOETHYLAMID DERIVATIVES AS IL-8 RECEPTOR MODULATORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND RHEUMATOID ARTHRITIS | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2004-08-19 | — | — | WO | disclosed |
| WO-2004062609-A2 | PYRIMIDINE DERIVATIVES AS IL-8 RECEPTOR ANTAGONISTS | PHARMACOPEIA, INC. (US) | 2004-07-29 | — | — | WO | disclosed |
| US-20040087601-A1 | Pyrimidine derivatives as IL-8 receptor antagonists | PHARMACOPEIA, LLC | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10676468-B2 | N-(3-heteroarylaryl)-4-arylarylcarboxamides and analogs as hedgehog pathway inhibitors and use thereof | SHH, GLI1, SMO | MEN1 2651/4885ALDH1A1 493/4885KMT2A 884/4885 |
| US-20040087601-A1 | Pyrimidine derivatives as IL-8 receptor antagonists | CXCL8, IL1RN, IL18 | MEN1 4787/4885ALDH1A1 1217/4885KMT2A 3913/4885 |
| US-20190255042-A1 | APPLICATION OF HEDGEHOG PATHWAY INHIBITOR IN TREATING FIBROSIS DISEASES | SHH, GLI1, SMO | MEN1 3372/4885ALDH1A1 418/4885KMT2A 2399/4885 |
| US-20150191460-A1 | N-(3-heteroarylaryl)-4-arylarylcarboxamides and Analogs as Hedgehog Pathway Inhibitors and Use Thereof | SHH, GLI1, SMO | MEN1 2651/4885ALDH1A1 493/4885KMT2A 884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.